Therapeutics News and Research

RSS

Combination of HUCBCs and Simvastatin offers promising therapy for stroke: Study

Researchers at the Henry Ford Health System (Detroit, MI) and colleagues at Saneron CCEL Therapeutics, Inc. of Tampa, Florida, have found that when human umbilical cord blood cells were transplanted into test rats modeled with stroke, the addition of Simvastatin to the HUCBCs significantly increased the therapeutic benefit of the HUCBCs.

21 Mar 2013

New biodegradable nanoparticles deliver inflammation-resolving drugs to sites of tissue injury

A multicenter team of researchers, including scientists at Columbia University Medical Center (CUMC), Brigham and Women's Hospital (BWH), Mount Sinai School of Medicine, and Massachusetts Institute of Technology, has developed biodegradable nanoparticles that are capable of delivering inflammation-resolving drugs to sites of tissue injury.

20 Mar 2013

Multipotent stem cells in deer antler may have regenerative uses in veterinary medicine

A team of researchers in Seoul, Korea have reported finding evidence that deer antlers - unique in that they regenerate annually - contain multipotent stem cells that could be useful for tissue regeneration in veterinary medicine.

20 Mar 2013

Protein derived from Pacific cod may inhibit prostate cancer, researchers say

Researchers at the University of Maryland School of Medicine have identified a peptide, or protein, derived from Pacific cod that may inhibit prostate cancer and possibly other cancers from spreading, according to preclinical research published online in the Proceedings of the National Academy of Sciences.

20 Mar 2013

Alnylam begins dosing in Phase I clinical trial with ALN-TTRsc for treatment of ATTR

Alnylam Pharmaceuticals a leading RNAi therapeutics company, announced today that it has initiated dosing in its Phase I clinical trial with ALN-TTRsc, an RNAi therapeutic targeting transthyretin (TTR) for the treatment of TTR-mediated amyloidosis (ATTR).

19 Mar 2013

Tivozanib: an interview with Stephen L. Eck, M.D., Ph.D., Vice President, Global Oncology, Astellas Pharma US, Inc. Global Development

Tivozanib is an oral, once-daily, investigational tyrosine kinase inhibitor, or TKI, that is being investigated for use in patients with advanced renal cell carcinoma (RCC), or kidney cancer.

19 Mar 2013

Columbia University Medical Center, NewYork-Presbyterian Hospital present research works at AAN meeting

The following research from Columbia University Medical Center and NewYork-Presbyterian Hospital is being presented at the 65th annual meeting of the American Academy of Neurology, March 16-23, 2013, in San Diego.

18 Mar 2013

Promising studies for Parkinson's to be presented at 65th AAN meeting

Three studies released today present possible positive news for people with Parkinson's disease. The studies, which will be presented at the American Academy of Neurology's 65th Annual Meeting in San Diego, March 16 to 23, 2013, report on treatments for blood pressure problems, the wearing-off that can occur when people have taken the main drug for Parkinson's for a long time, and for people early in the disease whose symptoms are not well-controlled by their main drugs.

15 Mar 2013

Phase 1b study of olesoxime initiated in multiple sclerosis (MS) patients

...

14 Mar 2013

Scientists to create new human monoclonal antibody targeting protein associated with cancer

Researchers have discovered a unique monoclonal antibody that can effectively reach inside a cancer cell, a key goal for these important anticancer agents, since most proteins that cause cancer or are associated with cancer are buried inside cancer cells.

14 Mar 2013

Scripps Research, Takeda Pharmaceutical to search for new drug targets for different diseases

The Scripps Research Institute and the Takeda Pharmaceutical Company have announced plans to expand their recent research collaboration to search for new drug targets for a variety of diseases.

14 Mar 2013

USPTO issues patent to Echo Therapeutics’ Prelude SkinPrep System

Echo Therapeutics, Inc., a company developing its needle-free Symphony CGM System as a non-invasive, wireless, transdermal continuous glucose monitoring system, today announced that the U.S. Patent and Trademark Office (USPTO) has issued U.S. Patent No. 8,386,027, "Skin Permeation Device For Analyte Sensing or Transdermal Drug Delivery," for the Prelude SkinPrep System, the skin permeation component of the Symphony CGM System.

12 Mar 2013

Laboratory for Molecular Biodiscovery, KU Leuven partner for €9.5M 'PharmaSea' project

KU Leuven scientist Camila Esguerra and the Laboratory for Molecular Biodiscovery are coordinating a €9.5 million, EU-funded project to collect and study marine microbes extracted from some of the ocean's deepest, most extreme - and as-yet-unexplored -biomes.

12 Mar 2013

Anti-cancer drug conjugates: an interview with Dr Andreas Menrad, CSO Ablynx and Dr Chris Martin, CEO Spirogen

Antibodies and in the case of Ablynx, Nanobodies, can be raised and selected to bind with high affinity selectively to cancer cells in a tumour. Cancer cells are exquisitely sensitive to certain toxins such as the PBDs produced by Spirogen.

12 Mar 2013

MiR-198 controls migration of skin cells necessary for wounds to close and heal

Patients with diseases such as diabetes suffer from painful wounds that take a long time to heal making them more susceptible to infections that could even lead to amputations. A*STAR's discovery paves the way for therapeutics to improve healing of such chronic wounds, which are a significant burden to patients.

11 Mar 2013

Genetic mutation that alters PIEZO1 ion channel in RBCs contributes to familial xerocytosis

A genetic mutation that alters the kinetics of an ion channel in red blood cells has been identified as the cause behind a hereditary anemia, according to a paper published this month in the Proceedings of the National Academy of Sciences by University at Buffalo scientists and colleagues.

11 Mar 2013

Wiley, BPS and ASPET partner to publish Pharmacology Research & Perspectives

John Wiley & Sons, Inc., The American Society for Pharmacology and Experimental Therapeutics (ASPET) and the British Pharmacological Society (BPS) announced today their partnership to publish the new open access, peer-reviewed journal, Pharmacology Research & Perspectives, which will open for submissions in April 2013.

8 Mar 2013

Acceleron commences ACE-536 phase 2 study in beta-thalassemia

Acceleron Pharma, Inc., a biopharmaceutical company developing protein therapeutics for cancer and orphan diseases, today announced the initiation of a phase 2 study of its novel, investigational protein therapeutic, ACE-536, to treat patients with beta-thalassemia, a genetic hematologic disorder causing chronic and life-threatening anemia and serious complications affecting the spleen, liver and heart.

7 Mar 2013

USF, Saneron receive patent for transplantation method using umbilical cord blood cells

Researchers at Saneron CCEL Therapeutics and the University of South Florida have received a patent relating to a method for obtaining and using umbilical cord blood cells from a donor or patient to provide neural cells for transplantation aimed at repairing a variety of neurodegenerative diseases of the brain and spinal cord, such as Parkinson's disease, Huntington's disease, multiple sclerosis, Alzheimer's disease as well as brain and spinal cord injury.

7 Mar 2013

UCLA scientists discover new genetic risk factor for Alzheimer's disease

Scientists at UCLA have discovered a new genetic risk factor for Alzheimer's disease by screening people's DNA and then using an advanced type of scan to visualize their brains' connections.

7 Mar 2013

Therapeutics News and Research

Combination of HUCBCs and Simvastatin offers promising therapy for stroke: Study

New biodegradable nanoparticles deliver inflammation-resolving drugs to sites of tissue injury

Multipotent stem cells in deer antler may have regenerative uses in veterinary medicine

Protein derived from Pacific cod may inhibit prostate cancer, researchers say

Alnylam begins dosing in Phase I clinical trial with ALN-TTRsc for treatment of ATTR

Tivozanib: an interview with Stephen L. Eck, M.D., Ph.D., Vice President, Global Oncology, Astellas Pharma US, Inc. Global Development

Columbia University Medical Center, NewYork-Presbyterian Hospital present research works at AAN meeting

Promising studies for Parkinson's to be presented at 65th AAN meeting

Phase 1b study of olesoxime initiated in multiple sclerosis (MS) patients

Scientists to create new human monoclonal antibody targeting protein associated with cancer

Scripps Research, Takeda Pharmaceutical to search for new drug targets for different diseases

USPTO issues patent to Echo Therapeutics’ Prelude SkinPrep System

Laboratory for Molecular Biodiscovery, KU Leuven partner for €9.5M 'PharmaSea' project

Anti-cancer drug conjugates: an interview with Dr Andreas Menrad, CSO Ablynx and Dr Chris Martin, CEO Spirogen

MiR-198 controls migration of skin cells necessary for wounds to close and heal

Genetic mutation that alters PIEZO1 ion channel in RBCs contributes to familial xerocytosis

Wiley, BPS and ASPET partner to publish Pharmacology Research & Perspectives

Acceleron commences ACE-536 phase 2 study in beta-thalassemia

USF, Saneron receive patent for transplantation method using umbilical cord blood cells

UCLA scientists discover new genetic risk factor for Alzheimer's disease

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News